【券商聚焦】西部证券首予维立志博-B“买入”评级指公司核心产品临床数据亮眼_老虎社区_美港股上老虎

【券商聚焦】西部证券首予维立志博-B“买入”评级指公司核心产品临床数据亮眼

金吾财讯02-20

（原标题：【券商聚焦】西部证券首予维立志博-B(09887)“买入”评级指公司核心产品临床数据亮眼）金吾财讯|西部证券发布研报指，维立志博-B(09887.HK)核心产品LBL-024（PD-L1/4-1BB双抗）在肺外神经内分泌癌(EP-NEC)临床数据优异，单药治疗3L+ EP-NEC ORR达33.3%，计划2026Q3递交BLA；LBL-034（GPRC5D/CD3双抗）在复发难治多发性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2612204261?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-20 10:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2612204261","market":"hk","top_or_hot":-1,"title":"【券商聚焦】西部证券首予维立志博-B“买入”评级 指公司核心产品临床数据亮眼","media":"金吾财讯","content":"<div>\n<p>（原标题：【券商聚焦】西部证券首予维立志博-B(09887)“买入”评级 指公司核心产品临床数据亮眼）金吾财讯|西部证券发布研报指，维立志博-B(09887.HK)核心产品LBL-024（PD-L1/4-1BB双抗）在肺外神经内分泌癌(EP-NEC)临床数据优异，单药治疗3L+ EP-NEC ORR达33.3%，计划2026Q3递交BLA；LBL-034（GPRC5D/CD3双抗）在复发难治多发性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】西部证券首予维立志博-B“买入”评级 指公司核心产品临床数据亮眼</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】西部证券首予维立志博-B“买入”评级 指公司核心产品临床数据亮眼\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-20 10:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（原标题：【券商聚焦】西部证券首予维立志博-B(09887)“买入”评级 指公司核心产品临床数据亮眼）金吾财讯|西部证券发布研报指，维立志博-B(09887.HK)核心产品LBL-024（PD-L1/4-1BB双抗）在肺外神经内分泌癌(EP-NEC)临床数据优异，单药治疗3L+ EP-NEC ORR达33.3%，计划2026Q3递交BLA；LBL-034（GPRC5D/CD3双抗）在复发难治多发性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b","article_id":"2612204261","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612204261","pubTimestamp":1771553054,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"金吾财讯|西部证券发布研报指，维立志博-B核心产品LBL-024在肺外神经内分泌癌临床数据优异，单药治疗3L+ EP-NEC ORR达33.3%，计划2026Q3递交BLA；LBL-034在复发难治多发性骨髓瘤I期ORR达82.5%。研报指出，LBL-024是全球首个进入注册临床的4-1BB靶向药物，已布局12个适应症，9项临床试验进行中。目标价未披露，首次覆盖给予\"买入\"评级。主要风险包括临床开发进度不及预期、商业化风险及核心人员流失。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09887":"维立志博-B"},"translate_title":"[Brokerage Focus] Western Securities first gave Weili Zhibo-B a \"buy\" rating, referring to the outstanding clinical data of the company's core products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1.5},"content_text":"（原标题：【券商聚焦】西部证券首予维立志博-B(09887)“买入”评级 指公司核心产品临床数据亮眼）金吾财讯|西部证券发布研报指，维立志博-B(09887.HK)核心产品LBL-024（PD-L1/4-1BB双抗）在肺外神经内分泌癌(EP-NEC)临床数据优异，单药治疗3L+ EP-NEC ORR达33.3%，计划2026Q3递交BLA；LBL-034（GPRC5D/CD3双抗）在复发难治多发性骨髓瘤I期ORR达82.5%。公司2027年有望进入商业化拐点。 研报指出，LBL-024是全球首个进入注册临床的4-1BB靶向药物，已布局12个适应症，9项临床试验进行中。关键数据：单药治疗2L+ EP-NEC mOS达11.9个月；联合化疗一线治疗EP-NEC ORR达75%。LBL-034在400-1200μg/kg剂量组CR率52.5%，MRD阴性率80%。 公司拥有三大技术平台，2025年10月LBL-047（BDCA2/TACI双抗）达成10亿美元海外授权。预计2025-2027年营收1.75/1.96/2.01亿元，当前股价对应PS 62/55/54倍。目标价未披露，首次覆盖给予\"买入\"评级。 主要风险包括临床开发进度不及预期、商业化风险及核心人员流失。报告强调LBL-024通过EP-NEC适应症快速上市，LBL-034有望成为Best-in-Class，后续ADC管线将丰富产品布局。2025H1公司现金储备4.52亿元，7月IPO募资13.63亿港元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}